<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537080</url>
  </required_header>
  <id_info>
    <org_study_id>201508-S22P</org_study_id>
    <nct_id>NCT02537080</nct_id>
  </id_info>
  <brief_title>The Effect of Nimodipine on the Postoperative Cognitive Dysfunction</brief_title>
  <official_title>The Effect of Nimodipine in the Preoperative Period on the Onset of Postoperative Cognitive Dysfunction in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Hradec Kralove</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The calcium channel blocker nimodipine dilates cerebral blood vessels and can pass through
      the blood-brain barrier, providing neuroprotective effects by selectively improving cerebral
      blood flow and inhibiting neuronal necrosis and apoptosis. Nimodipine significantly inhibited
      the production of tumor necrosis factor TNF-α and interleukin IL-1β, and also of nitric oxide
      and prostaglandin E2 from lipopolysaccharide-stimulated microglia. Abnormal cytokine networks
      are important in the development of nerve cell damage that leads to cognitive impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients aged above 60 years undergoing planned neurosurgical operations in the duration
      up to 4 hours under general anesthesia will be included in the study. The patients will not
      be sedated by any type of benzodiazepine. A dose of 30 mg nimodipine or placebo will be
      applied 45 minutes before the surgery according to the randomization. Anesthesia will be
      managed according to the standardised protocol. Concentration of desflurane will be adjusted
      according to entropy values (target 40-50). Analgetics will be applied according to surgical
      pleth index (SPI) values. Sufentanil will not be applied in the last 15 minutes. Extubation
      will be performed at the operating theatre when meeting all extubation criteria including
      train of four ratio (TOFR) above 92%. Neither syntophylline, nor pharmacological
      decurarization (syntostigmine) will be applied to the patients.During the surgery, blood
      pressure will be maintained within ± 15% of the patient's normal blood pressure. Cognitive
      dysfunction tests will be executed on the day before the surgery, two hours after the surgery
      and on the third postoperative day.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    higher POCD in nimodipine Group
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive behavior</measure>
    <time_frame>within the first 3 days after surgery</time_frame>
    <description>measured by Addenbrooks cognitive test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Nimodipine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tbl of 30 mg nimodipine will be administered orally with premedication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tbl of placebo will be administered orally with premedication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimodipine group</intervention_name>
    <description>the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure</description>
    <arm_group_label>Nimodipine group</arm_group_label>
    <other_name>nimodipine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glascow coma scale GCS 15 preoperatively

          -  American Society of Anesthesiologists ASA risk I - III

          -  planned brain surgery

          -  duration of procedure up to 4 hours.

        Exclusion Criteria:

          -  blood pressure below 130/80 torr preoperatively

          -  previous vascular surgery

          -  concomitant use of antiepileptic drugs, rifampicin

          -  allergy to nimodipine

          -  known liver cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vlasta Dostalova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Hradec Kralove</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>October 15, 2016</last_update_submitted>
  <last_update_submitted_qc>October 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Hradec Kralove</investigator_affiliation>
    <investigator_full_name>Dostalova Vlasta, MD, PhD</investigator_full_name>
    <investigator_title>Vlasta Dostalova, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Postoperative cognitive dysfunction</keyword>
  <keyword>Nimodipin</keyword>
  <keyword>Anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

